Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-κB signaling
Apigenin is a naturally occurring compound with anti-inflammatory, antioxidant, and anticancer properties. Here, we investigated the effects of apigeninin inflammatory bowel disease (IBD) and colitis-associated cancer (CAC). Apigenin effectively inhibited ulcerative colitis, a type of IBD, and CAC. Apigenin decreased myeloperoxidase (MPO), inflammatory cytokine and COX-2 levels, and it attenuated inflammatory cell infiltration in treated colon tissues as compared to untreated model colon tissues. Apigenin also reduced NF-κB and STAT3 activity in vitro and in vivo, thereby inhibiting inflammation and inflammation-induced carcinogenesis. Thus apigenin appears to inhibit inflammation and inflammation-induced carcinogenesisin IBD and CAC by suppressing STAT3-NF-κB signaling.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 59 vom: 21. Nov., Seite 100216-100226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ai, Xiao-Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.22145 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM279104545 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM279104545 | ||
| 003 | DE-627 | ||
| 005 | 20231225022205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.22145 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0930.xml |
| 035 | |a (DE-627)NLM279104545 | ||
| 035 | |a (NLM)29245972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ai, Xiao-Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-κB signaling |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Apigenin is a naturally occurring compound with anti-inflammatory, antioxidant, and anticancer properties. Here, we investigated the effects of apigeninin inflammatory bowel disease (IBD) and colitis-associated cancer (CAC). Apigenin effectively inhibited ulcerative colitis, a type of IBD, and CAC. Apigenin decreased myeloperoxidase (MPO), inflammatory cytokine and COX-2 levels, and it attenuated inflammatory cell infiltration in treated colon tissues as compared to untreated model colon tissues. Apigenin also reduced NF-κB and STAT3 activity in vitro and in vivo, thereby inhibiting inflammation and inflammation-induced carcinogenesis. Thus apigenin appears to inhibit inflammation and inflammation-induced carcinogenesisin IBD and CAC by suppressing STAT3-NF-κB signaling | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CAC | |
| 650 | 4 | |a IBD | |
| 650 | 4 | |a NF-κB | |
| 650 | 4 | |a STAT3 | |
| 650 | 4 | |a apigenin | |
| 700 | 1 | |a Qin, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hui-Jua |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Zhan-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jia-Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Wei-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yan-Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hong-Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Cheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 59 vom: 21. Nov., Seite 100216-100226 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:59 |g day:21 |g month:11 |g pages:100216-100226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.22145 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 59 |b 21 |c 11 |h 100216-100226 | ||